Anxo Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Anxo Pharmaceutical's earnings have been declining at an average annual rate of -24.1%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 1.5% per year.
Belangrijke informatie
-24.1%
Groei van de winst
-25.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 18.5% |
| Inkomstengroei | 1.5% |
| Rendement op eigen vermogen | -1.0% |
| Nettomarge | -2.2% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Anxo Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 910 | -20 | 221 | 129 |
| 31 Mar 24 | 925 | 1 | 213 | 134 |
| 31 Dec 23 | 940 | 22 | 204 | 139 |
| 30 Sep 23 | 941 | 28 | 199 | 141 |
| 30 Jun 23 | 941 | 33 | 193 | 144 |
| 31 Mar 23 | 904 | 10 | 190 | 142 |
| 31 Dec 22 | 866 | -13 | 186 | 140 |
| 30 Sep 22 | 830 | -17 | 183 | 134 |
| 30 Jun 22 | 793 | -21 | 180 | 127 |
| 31 Mar 22 | 809 | -1 | 180 | 119 |
| 31 Dec 21 | 824 | 19 | 180 | 111 |
| 30 Sep 21 | 835 | 19 | 185 | 111 |
| 30 Jun 21 | 845 | 19 | 191 | 110 |
| 31 Mar 21 | 856 | 25 | 195 | 105 |
| 31 Dec 20 | 866 | 31 | 199 | 101 |
| 30 Sep 20 | 867 | 25 | 199 | 88 |
| 30 Jun 20 | 867 | 19 | 200 | 76 |
| 31 Mar 20 | 873 | 22 | 204 | 71 |
| 31 Dec 19 | 878 | 24 | 207 | 67 |
| 30 Sep 19 | 863 | 20 | 208 | 66 |
| 30 Jun 19 | 847 | 16 | 208 | 64 |
| 31 Mar 19 | 849 | 22 | 211 | 68 |
| 31 Dec 18 | 850 | 29 | 214 | 71 |
| 30 Sep 18 | 823 | 20 | 216 | 70 |
| 30 Jun 18 | 795 | 11 | 218 | 69 |
| 31 Mar 18 | 750 | -9 | 218 | 63 |
| 31 Dec 17 | 705 | -29 | 218 | 57 |
| 30 Sep 17 | 692 | -22 | 218 | 58 |
| 30 Jun 17 | 679 | -15 | 219 | 59 |
| 31 Mar 17 | 660 | -17 | 218 | 57 |
| 31 Dec 16 | 642 | -20 | 218 | 56 |
| 31 Dec 15 | 631 | -24 | 209 | 31 |
| 31 Dec 14 | 643 | 26 | 185 | 27 |
Kwaliteitswinsten: 6677 is currently unprofitable.
Groeiende winstmarge: 6677 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 6677 is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.
Versnelling van de groei: Unable to compare 6677's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 6677 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Rendement op eigen vermogen
Hoge ROE: 6677 has a negative Return on Equity (-1.02%), as it is currently unprofitable.